Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo attack on prostate cancer shows promise in early trial

NCT ID NCT04126070

Ongoing Disease control Sponsor: Xiao X. Wei, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The trial enrolls 47 participants with specific genetic features or inflamed tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nivolumab (immunotherapy) combined with docetaxel (chemotherapy) and androgen deprivation therapy (hormone therapy)
What this could lead to
If successful, this could point toward a more effective treatment option for men with advanced prostate cancer that has specific genetic features.
What could go wrong
This is an early phase 2 trial with only 47 participants, so results may not apply to all patients. Combining three strong therapies also raises the risk of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate adenocarcinoma prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HORMONE SENSITIVE PROSTATE CANCER METASTASIS PROSTATE ADENOCARCINOMA PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21218, United States

  • University of California, San Diego

    La Jolla, California, 92093, United States

  • University of Wisconsin

    Madison, Wisconsin, 53706, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.